Pfizer (NYSE:PFE) recently received a CDC recommendation for wider use of its RSV vaccine, ABRYSVO, in adults aged 50-59 at ...

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in ...

The U.S. CDC's Advisory Committee recommends the use of GSK and Pfizer's RSV vaccines in adults aged 50-59 who are at high ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

Significant delays in core FDA functions — such as approving amendments to clinical trials and guiding companies through ...

The Trump administration is considering eliminating dozens of programs at HHS amid a mass reorganization of the agency.